アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

henry schein, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. none. 8.1 pregnancy animal reproduction studies have not been conducted with atropine. it also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. 8.3 nursing mothers trace amounts of atropine was found in breast milk. the clinical impact of this is not known. 8.5 geriatric use an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

henry schein, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. none. 8.1 pregnancy risk summary limited available data with atropine sulfate injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes (see data). there are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see clinical considerations). animal reproduction studies have not been conducted with atropine sulfate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pr

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

meridian medical technologies, llc - atropine (unii: 7c0697dr9i) (atropine - unii:7c0697dr9i) - atropine 2.1 mg in 0.7 ml - atnaa is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity in adults. none. risk summary atropine readily crosses the placental barrier and enters fetal circulation. there are no adequate data on the developmental risk associated with the use of atropine, pralidoxime chloride, or the combination in pregnant women. adequate animal reproduction studies have not been conducted with atropine, pralidoxime chloride, or the combination. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary atropine has been reported to be excreted in human milk. it is not known whether pralidoxime chloride is excreted in human milk. there are no data on the effects of atropine or pralidoxime chloride on the breastfed infant or the effects of the drugs on milk production. the developmental and health benefits of breastfeeding should be

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

cardinal health - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp is indicated (1) as an antisialogogue for preanesthetic medication to prevent or reduce secretions of the respiratory tract, (2) to restore cardiac rate and arterial pressure during anesthesia when vagal stimulation produced by intra-abdominal surgical traction causes a sudden decrease in pulse rate and cardiac action, (3) to lessen the degree of atrioventricular (a-v) heart block when increased vagal tone is a major factor in the conduction defect as in some cases due to digitalis, (4) to overcome severe bradycardia and syncope due to a hyperactive carotid sinus reflex, (5) as an antidote (with external cardiac massage) for cardiovascular collapse from the injudicious use of a choline ester (cholinergic) drug, (6) in the treatment of anticholinesterase poisoning from organophosphorus insecticides, and (7) as an antidote for the “rapid” type of mushroom poisoning due to the presence of the alkaloid, muscarine, in certain species of fungus such as amanita muscaria . atropine ge

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

remedyrepack inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. it may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. the antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. for ureteral and biliary colic, atropine concomitantly with morphine may be indicated. atropine relaxes the upper gi tract and colon during hypotonic radiography. in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. it is also used as an antidote for mushroom poisoning due to muscarine in certain species such as amanita muscaria . atropine sulfate

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - atropine sulfate monohydrate, quantity: 1.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - indications as at 23 october 2001: preanaesthetic medication to reduce salivary secretions and bronchial secretions. to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia. management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability. concurrent administration with anticholinesterase agents (eg. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation. for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, usp 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution 1% is administered to a nursing woman. due to the potential for systemic

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, usp 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, usp 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, usp 1% is administered to a nursing woman. due to the potential fo

イスラエル - 英語 - Ministry of Health

teva israel ltd - atropine sulfate - solution for injection - atropine sulfate 1 mg/ml - atropine - atropine - preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. treatment of sinus bradycardia, particularly if complicated by hypotension. antidote in poisoning by organophosphorus.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

genus lifesciences inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), homatropine methylbromide (unii: 68jrs2hc1c) (methylhomatropine - unii:p97ogj7l1l) - hydrocodone bitartrate and homatropine methylbromide is indicated for the symptomatic relief of cough in adult patients 18 years of age and older. limitations of use: - not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4)]. - contraindicated in pediatric patients less than 6 years of age [see contraindications (4)]. - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)], reserve hydrocodone bitartrate and homatropine methylbromide for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. hydrocodone bitartrate and homatropine methylbromide is contraindicated for: - all pediatric patients younger than 6 years of age [see warnings and precautions (5.2, 5.3), use in specific populations (8.4)]. - significant respiratory depression [see warnings and precautions (5.2)]